Latest Medicine stories from Life.
Strategic angle: Mayo Clinic researchers developed an experimental nanotherapy that delivers two cancer drugs directly to brain tumors, extending survival in preclinical models.
Strategic angle: A bill is moving through the Colorado legislature that would exempt orphan drugs from pricing caps that might be pursued by the state.
Strategic angle: The war in Iran has slowed down international shipping, much of which contains medical and humanitarian goods destined for Asia and Africa.
Strategic angle: Innovative blood-catalyzed chemistry paves the way for advanced medical applications.
Strategic angle: A reactivation of the virus that causes chickenpox, the illness can be miserable. Here's what to know about early warning signs, long-term symptoms and some surprising news about the vaccine.
France's foreign ministry expresses consternation over the execution of a French citizen sentenced to death in China.
Strategic angle: Smaller biotechs negotiate with the White House while addressing the trust gap in medicine.
Strategic angle: “The volume of evidence behind a therapy has become inversely correlated with public trust in it,” writes Vikas Patel.
Strategic angle: A Supreme Court ruling this week on gender and sexuality 'conversion therapy' could narrow the authority of state medical boards over care involving speech.
Strategic angle: A new way to define obesity aims to sharpen the diagnosis. Critics warn it could delay care, exclude diabetes, and deepen inequities in accessing treatment.
Strategic angle: The daily pill called Foundayo got a fast track through the Food and Drug Administration.
Strategic angle: A delayed FDA decision for Orca Bio, new questions about pharma-telehealth tie-ups, and more
Strategic angle: A new study explores whether incorporating psychotherapy with ketamine treatment enhances its effectiveness.
Strategic angle: “Rigorously derived evidence for the medical efficacy of marijuana is thin,” writes Kevin Sabet.
Strategic angle: A breakthrough in the fight against superbugs and antimicrobial resistance.
Strategic angle: Drugmakers are postponing the release of new medicines in Europe due to shifting pricing policies and pressures from the U.S.
Strategic angle: Here’s Why Fresenius Medical Care AG (FMS) Remains Attractive
Strategic angle: Takeda Pharmaceuticals, the largest biopharma employer in Mass., will lay off 250 workers in Cambridge beginning in July.
Strategic angle: The organization criticized Gilead Sciences after months of negotiations for a limited supply of lenacapavir.
Strategic angle: The drug demonstrates improved skin clearance, marking a significant advancement in lupus treatment.